Gerard Brophy - Jan 2, 2022 Form 4 Insider Report for Avantor, Inc. (AVTR)

Role
EVP, Biopharma Production
Signature
/s/ Scott Baker, as Attorney-in-Fact
Stock symbol
AVTR
Transactions as of
Jan 2, 2022
Transactions value $
-$2,047,240
Form type
4
Date filed
1/5/2022, 03:59 PM
Previous filing
Aug 2, 2021
Next filing
Feb 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTR Common Stock Tax liability -$275K -6.52K -4.36% $42.14 143K Jan 2, 2022 Direct F1
transaction AVTR Common Stock Options Exercise $1.1M +59.4K +41.59% $18.45 202K Jan 3, 2022 Direct
transaction AVTR Common Stock Sale -$2.42M -59.4K -29.37% $40.77 143K Jan 3, 2022 Direct F2, F3
transaction AVTR Common Stock Sale -$446K -11.6K -8.09% $38.65 131K Jan 5, 2022 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTR Stock Options (Right to Buy) Options Exercise $0 -59.4K -50% $0.00 59.4K Jan 3, 2022 Common Stock 59.4K $18.45 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs.
F2 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.27 to $41.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.44 to $38.87, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
F5 Reflects an initial grant of 178,253 stock options that vest in three equal installments beginning on January 2, 2021.